https://keshavmed.com/news/13000-people-with-hiv-to-be-offered-new-long-acting-treatment-jersey-evening-post-ar/ 2026-07-21T02:31:10+00:00 https://keshavmed.com/news/13000-people-with-hiv-to-be-offered-new-long-acting-treatment-jersey-evening-post-ru/ 2026-07-21T02:31:10+00:00 https://keshavmed.com/news/13000-people-with-hiv-to-be-offered-new-long-acting-treatment-jersey-evening-post-es/ 2026-07-21T02:31:09+00:00 https://keshavmed.com/news/13000-people-with-hiv-to-be-offered-new-long-acting-treatment-jersey-evening-post-pt/ 2026-07-21T02:31:09+00:00 https://keshavmed.com/news/13000-people-with-hiv-to-be-offered-new-long-acting-treatment-jersey-evening-post-de/ 2026-07-21T02:31:08+00:00 https://keshavmed.com/news/13000-people-with-hiv-to-be-offered-new-long-acting-treatment-jersey-evening-post-ja/ 2026-07-21T02:31:08+00:00 https://keshavmed.com/news/13000-people-with-hiv-to-be-offered-new-long-acting-treatment-jersey-evening-post-zh-tw/ 2026-07-21T02:31:07+00:00 https://keshavmed.com/news/13000-people-with-hiv-to-be-offered-new-long-acting-treatment-jersey-evening-post-fr/ 2026-07-21T02:31:07+00:00 https://keshavmed.com/news/13000-people-with-hiv-to-be-offered-new-long-acting-treatment-jersey-evening-post/ 2026-07-21T02:31:06+00:00 https://keshavmed.com/news/novartis-reports-positive-data-of-asciminib-in-ascembl-trial-clinical-trials-arena-vi/ 2026-07-21T02:29:57+00:00 https://keshavmed.com/news/novartis-reports-positive-data-of-asciminib-in-ascembl-trial-clinical-trials-arena-ms/ 2026-07-21T02:29:57+00:00 https://keshavmed.com/news/novartis-reports-positive-data-of-asciminib-in-ascembl-trial-clinical-trials-arena-id/ 2026-07-21T02:29:56+00:00 https://keshavmed.com/news/novartis-reports-positive-data-of-asciminib-in-ascembl-trial-clinical-trials-arena-th/ 2026-07-21T02:29:56+00:00 https://keshavmed.com/news/novartis-reports-positive-data-of-asciminib-in-ascembl-trial-clinical-trials-arena-ru/ 2026-07-21T02:29:55+00:00 https://keshavmed.com/news/novartis-reports-positive-data-of-asciminib-in-ascembl-trial-clinical-trials-arena-es/ 2026-07-21T02:29:54+00:00 https://keshavmed.com/news/novartis-reports-positive-data-of-asciminib-in-ascembl-trial-clinical-trials-arena-ar/ 2026-07-21T02:29:54+00:00 https://keshavmed.com/news/novartis-reports-positive-data-of-asciminib-in-ascembl-trial-clinical-trials-arena-ja/ 2026-07-21T02:29:53+00:00 https://keshavmed.com/news/novartis-reports-positive-data-of-asciminib-in-ascembl-trial-clinical-trials-arena-pt/ 2026-07-21T02:29:53+00:00 https://keshavmed.com/news/novartis-reports-positive-data-of-asciminib-in-ascembl-trial-clinical-trials-arena-de/ 2026-07-21T02:29:52+00:00 https://keshavmed.com/news/novartis-reports-positive-data-of-asciminib-in-ascembl-trial-clinical-trials-arena-fr/ 2026-07-21T02:29:52+00:00 https://keshavmed.com/news/novartis-reports-positive-data-of-asciminib-in-ascembl-trial-clinical-trials-arena/ 2026-07-21T02:29:51+00:00 https://keshavmed.com/news/novartis-reports-positive-data-of-asciminib-in-ascembl-trial-clinical-trials-arena-zh-tw/ 2026-07-21T02:29:51+00:00 https://keshavmed.com/news/fda-to-prioritize-review-of-novartis-stamp-inhibitor-asciminib-for-chronic-myeloid-leukemia-drugdiscoverytrends-com-vi/ 2026-07-21T02:29:30+00:00 https://keshavmed.com/news/fda-to-prioritize-review-of-novartis-stamp-inhibitor-asciminib-for-chronic-myeloid-leukemia-drugdiscoverytrends-com-ms/ 2026-07-21T02:29:30+00:00 https://keshavmed.com/news/fda-to-prioritize-review-of-novartis-stamp-inhibitor-asciminib-for-chronic-myeloid-leukemia-drugdiscoverytrends-com-th/ 2026-07-21T02:29:29+00:00 https://keshavmed.com/news/fda-to-prioritize-review-of-novartis-stamp-inhibitor-asciminib-for-chronic-myeloid-leukemia-drugdiscoverytrends-com-ru/ 2026-07-21T02:29:28+00:00 https://keshavmed.com/news/fda-to-prioritize-review-of-novartis-stamp-inhibitor-asciminib-for-chronic-myeloid-leukemia-drugdiscoverytrends-com-id/ 2026-07-21T02:29:28+00:00 https://keshavmed.com/news/fda-to-prioritize-review-of-novartis-stamp-inhibitor-asciminib-for-chronic-myeloid-leukemia-drugdiscoverytrends-com-ar/ 2026-07-21T02:29:27+00:00 https://keshavmed.com/news/fda-to-prioritize-review-of-novartis-stamp-inhibitor-asciminib-for-chronic-myeloid-leukemia-drugdiscoverytrends-com-es/ 2026-07-21T02:29:26+00:00 https://keshavmed.com/news/fda-to-prioritize-review-of-novartis-stamp-inhibitor-asciminib-for-chronic-myeloid-leukemia-drugdiscoverytrends-com-ja/ 2026-07-21T02:29:25+00:00 https://keshavmed.com/news/fda-to-prioritize-review-of-novartis-stamp-inhibitor-asciminib-for-chronic-myeloid-leukemia-drugdiscoverytrends-com-pt/ 2026-07-21T02:29:25+00:00 https://keshavmed.com/news/fda-to-prioritize-review-of-novartis-stamp-inhibitor-asciminib-for-chronic-myeloid-leukemia-drugdiscoverytrends-com-fr/ 2026-07-21T02:29:24+00:00 https://keshavmed.com/news/fda-to-prioritize-review-of-novartis-stamp-inhibitor-asciminib-for-chronic-myeloid-leukemia-drugdiscoverytrends-com-de/ 2026-07-21T02:29:24+00:00 https://keshavmed.com/news/fda-to-prioritize-review-of-novartis-stamp-inhibitor-asciminib-for-chronic-myeloid-leukemia-drugdiscoverytrends-com-zh-tw/ 2026-07-21T02:29:23+00:00 https://keshavmed.com/news/fda-to-prioritize-review-of-novartis-stamp-inhibitor-asciminib-for-chronic-myeloid-leukemia-drugdiscoverytrends-com/ 2026-07-21T02:29:22+00:00 https://keshavmed.com/news/fda-approves-asciminib-for-philadelphia-chromosome-positive-cml-the-asco-post-th/ 2026-07-21T02:28:56+00:00 https://keshavmed.com/news/fda-approves-asciminib-for-philadelphia-chromosome-positive-cml-the-asco-post-vi/ 2026-07-21T02:28:56+00:00 https://keshavmed.com/news/fda-approves-asciminib-for-philadelphia-chromosome-positive-cml-the-asco-post-ms/ 2026-07-21T02:28:56+00:00 https://keshavmed.com/news/fda-approves-asciminib-for-philadelphia-chromosome-positive-cml-the-asco-post-ru/ 2026-07-21T02:28:55+00:00 https://keshavmed.com/news/fda-approves-asciminib-for-philadelphia-chromosome-positive-cml-the-asco-post-id/ 2026-07-21T02:28:55+00:00 https://keshavmed.com/news/fda-approves-asciminib-for-philadelphia-chromosome-positive-cml-the-asco-post-ar/ 2026-07-21T02:28:54+00:00 https://keshavmed.com/news/fda-approves-asciminib-for-philadelphia-chromosome-positive-cml-the-asco-post-pt/ 2026-07-21T02:28:53+00:00 https://keshavmed.com/news/fda-approves-asciminib-for-philadelphia-chromosome-positive-cml-the-asco-post-es/ 2026-07-21T02:28:53+00:00 https://keshavmed.com/news/fda-approves-asciminib-for-philadelphia-chromosome-positive-cml-the-asco-post-de/ 2026-07-21T02:28:52+00:00 https://keshavmed.com/news/fda-approves-asciminib-for-philadelphia-chromosome-positive-cml-the-asco-post-ja/ 2026-07-21T02:28:52+00:00 https://keshavmed.com/news/fda-approves-asciminib-for-philadelphia-chromosome-positive-cml-the-asco-post-zh-tw/ 2026-07-21T02:28:51+00:00 https://keshavmed.com/news/fda-approves-asciminib-for-philadelphia-chromosome-positive-cml-the-asco-post-fr/ 2026-07-21T02:28:51+00:00 https://keshavmed.com/news/fda-approves-asciminib-for-philadelphia-chromosome-positive-cml-the-asco-post/ 2026-07-21T02:28:50+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-asciminib-scemblix-for-chronic-myeloid-leukemia-oncology-news-central-vi/ 2026-07-21T02:28:31+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-asciminib-scemblix-for-chronic-myeloid-leukemia-oncology-news-central-ms/ 2026-07-21T02:28:31+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-asciminib-scemblix-for-chronic-myeloid-leukemia-oncology-news-central-th/ 2026-07-21T02:28:30+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-asciminib-scemblix-for-chronic-myeloid-leukemia-oncology-news-central-ru/ 2026-07-21T02:28:29+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-asciminib-scemblix-for-chronic-myeloid-leukemia-oncology-news-central-id/ 2026-07-21T02:28:29+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-asciminib-scemblix-for-chronic-myeloid-leukemia-oncology-news-central-es/ 2026-07-21T02:28:28+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-asciminib-scemblix-for-chronic-myeloid-leukemia-oncology-news-central-ar/ 2026-07-21T02:28:28+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-asciminib-scemblix-for-chronic-myeloid-leukemia-oncology-news-central-pt/ 2026-07-21T02:28:27+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-asciminib-scemblix-for-chronic-myeloid-leukemia-oncology-news-central-de/ 2026-07-21T02:28:26+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-asciminib-scemblix-for-chronic-myeloid-leukemia-oncology-news-central-ja/ 2026-07-21T02:28:26+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-asciminib-scemblix-for-chronic-myeloid-leukemia-oncology-news-central-fr/ 2026-07-21T02:28:25+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-asciminib-scemblix-for-chronic-myeloid-leukemia-oncology-news-central/ 2026-07-21T02:28:24+00:00 https://keshavmed.com/news/fda-grants-accelerated-approval-to-asciminib-scemblix-for-chronic-myeloid-leukemia-oncology-news-central-zh-tw/ 2026-07-21T02:28:24+00:00 https://keshavmed.com/news/asciminib-monotherapy-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-without-bcrabl1-nature-ms/ 2026-07-21T02:28:09+00:00 https://keshavmed.com/news/asciminib-monotherapy-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-without-bcrabl1-nature-vi/ 2026-07-21T02:28:08+00:00 https://keshavmed.com/news/asciminib-monotherapy-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-without-bcrabl1-nature-th/ 2026-07-21T02:28:07+00:00 https://keshavmed.com/news/asciminib-monotherapy-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-without-bcrabl1-nature-id/ 2026-07-21T02:28:06+00:00 https://keshavmed.com/news/asciminib-monotherapy-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-without-bcrabl1-nature-ar/ 2026-07-21T02:28:05+00:00 https://keshavmed.com/news/asciminib-monotherapy-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-without-bcrabl1-nature-ru/ 2026-07-21T02:28:05+00:00 https://keshavmed.com/news/asciminib-monotherapy-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-without-bcrabl1-nature-pt/ 2026-07-21T02:28:03+00:00 https://keshavmed.com/news/asciminib-monotherapy-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-without-bcrabl1-nature-es/ 2026-07-21T02:28:03+00:00 https://keshavmed.com/news/asciminib-monotherapy-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-without-bcrabl1-nature-ja/ 2026-07-21T02:28:02+00:00 https://keshavmed.com/news/asciminib-monotherapy-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-without-bcrabl1-nature-de/ 2026-07-21T02:28:00+00:00 https://keshavmed.com/news/asciminib-monotherapy-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-without-bcrabl1-nature-zh-tw/ 2026-07-21T02:27:59+00:00 https://keshavmed.com/news/asciminib-monotherapy-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-without-bcrabl1-nature-fr/ 2026-07-21T02:27:59+00:00 https://keshavmed.com/news/asciminib-monotherapy-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-without-bcrabl1-nature/ 2026-07-21T02:27:57+00:00 https://keshavmed.com/news/asco-2025-asciminib-demonstrates-superiority-compared-with-nilotinib-in-ph-cml-cp-pharmacy-times-ms/ 2026-07-21T02:27:49+00:00 https://keshavmed.com/news/asco-2025-asciminib-demonstrates-superiority-compared-with-nilotinib-in-ph-cml-cp-pharmacy-times-th/ 2026-07-21T02:27:48+00:00 https://keshavmed.com/news/asco-2025-asciminib-demonstrates-superiority-compared-with-nilotinib-in-ph-cml-cp-pharmacy-times-vi/ 2026-07-21T02:27:48+00:00 https://keshavmed.com/news/asco-2025-asciminib-demonstrates-superiority-compared-with-nilotinib-in-ph-cml-cp-pharmacy-times-id/ 2026-07-21T02:27:47+00:00 https://keshavmed.com/news/asco-2025-asciminib-demonstrates-superiority-compared-with-nilotinib-in-ph-cml-cp-pharmacy-times-ar/ 2026-07-21T02:27:46+00:00 https://keshavmed.com/news/asco-2025-asciminib-demonstrates-superiority-compared-with-nilotinib-in-ph-cml-cp-pharmacy-times-ru/ 2026-07-21T02:27:46+00:00 https://keshavmed.com/news/asco-2025-asciminib-demonstrates-superiority-compared-with-nilotinib-in-ph-cml-cp-pharmacy-times-es/ 2026-07-21T02:27:45+00:00 https://keshavmed.com/news/asco-2025-asciminib-demonstrates-superiority-compared-with-nilotinib-in-ph-cml-cp-pharmacy-times-ja/ 2026-07-21T02:27:44+00:00 https://keshavmed.com/news/asco-2025-asciminib-demonstrates-superiority-compared-with-nilotinib-in-ph-cml-cp-pharmacy-times-pt/ 2026-07-21T02:27:44+00:00 https://keshavmed.com/news/asco-2025-asciminib-demonstrates-superiority-compared-with-nilotinib-in-ph-cml-cp-pharmacy-times-de/ 2026-07-21T02:27:43+00:00 https://keshavmed.com/news/asco-2025-asciminib-demonstrates-superiority-compared-with-nilotinib-in-ph-cml-cp-pharmacy-times-zh-tw/ 2026-07-21T02:27:42+00:00 https://keshavmed.com/news/asco-2025-asciminib-demonstrates-superiority-compared-with-nilotinib-in-ph-cml-cp-pharmacy-times-fr/ 2026-07-21T02:27:42+00:00 https://keshavmed.com/news/asco-2025-asciminib-demonstrates-superiority-compared-with-nilotinib-in-ph-cml-cp-pharmacy-times/ 2026-07-21T02:27:41+00:00 https://keshavmed.com/news/alembic-pharma-gets-usfda-approval-for-leukaemia-drug-dasatinib-healthcare-radius-ms/ 2026-07-21T02:27:33+00:00 https://keshavmed.com/news/alembic-pharma-gets-usfda-approval-for-leukaemia-drug-dasatinib-healthcare-radius-vi/ 2026-07-21T02:27:32+00:00 https://keshavmed.com/news/alembic-pharma-gets-usfda-approval-for-leukaemia-drug-dasatinib-healthcare-radius-id/ 2026-07-21T02:27:31+00:00 https://keshavmed.com/news/alembic-pharma-gets-usfda-approval-for-leukaemia-drug-dasatinib-healthcare-radius-th/ 2026-07-21T02:27:31+00:00 https://keshavmed.com/news/alembic-pharma-gets-usfda-approval-for-leukaemia-drug-dasatinib-healthcare-radius-ar/ 2026-07-21T02:27:30+00:00 https://keshavmed.com/news/alembic-pharma-gets-usfda-approval-for-leukaemia-drug-dasatinib-healthcare-radius-ru/ 2026-07-21T02:27:30+00:00 https://keshavmed.com/news/alembic-pharma-gets-usfda-approval-for-leukaemia-drug-dasatinib-healthcare-radius-es/ 2026-07-21T02:27:29+00:00 https://keshavmed.com/news/alembic-pharma-gets-usfda-approval-for-leukaemia-drug-dasatinib-healthcare-radius-ja/ 2026-07-21T02:27:28+00:00 https://keshavmed.com/news/alembic-pharma-gets-usfda-approval-for-leukaemia-drug-dasatinib-healthcare-radius-pt/ 2026-07-21T02:27:28+00:00 https://keshavmed.com/news/alembic-pharma-gets-usfda-approval-for-leukaemia-drug-dasatinib-healthcare-radius-fr/ 2026-07-21T02:27:27+00:00 https://keshavmed.com/news/alembic-pharma-gets-usfda-approval-for-leukaemia-drug-dasatinib-healthcare-radius-de/ 2026-07-21T02:27:27+00:00 https://keshavmed.com/news/alembic-pharma-gets-usfda-approval-for-leukaemia-drug-dasatinib-healthcare-radius-zh-tw/ 2026-07-21T02:27:26+00:00 https://keshavmed.com/news/alembic-pharma-gets-usfda-approval-for-leukaemia-drug-dasatinib-healthcare-radius/ 2026-07-21T02:27:25+00:00 https://keshavmed.com/news/tern-701-earns-fda-breakthrough-therapy-designation-in-ph-cml-cancernetwork-vi/ 2026-07-21T02:27:15+00:00 https://keshavmed.com/news/tern-701-earns-fda-breakthrough-therapy-designation-in-ph-cml-cancernetwork-ms/ 2026-07-21T02:27:15+00:00 https://keshavmed.com/news/tern-701-earns-fda-breakthrough-therapy-designation-in-ph-cml-cancernetwork-th/ 2026-07-21T02:27:14+00:00 https://keshavmed.com/news/tern-701-earns-fda-breakthrough-therapy-designation-in-ph-cml-cancernetwork-id/ 2026-07-21T02:27:13+00:00 https://keshavmed.com/news/tern-701-earns-fda-breakthrough-therapy-designation-in-ph-cml-cancernetwork-ar/ 2026-07-21T02:27:12+00:00 https://keshavmed.com/news/tern-701-earns-fda-breakthrough-therapy-designation-in-ph-cml-cancernetwork-ru/ 2026-07-21T02:27:12+00:00 https://keshavmed.com/news/tern-701-earns-fda-breakthrough-therapy-designation-in-ph-cml-cancernetwork-es/ 2026-07-21T02:27:11+00:00 https://keshavmed.com/news/tern-701-earns-fda-breakthrough-therapy-designation-in-ph-cml-cancernetwork-pt/ 2026-07-21T02:27:10+00:00 https://keshavmed.com/news/tern-701-earns-fda-breakthrough-therapy-designation-in-ph-cml-cancernetwork-ja/ 2026-07-21T02:27:09+00:00 https://keshavmed.com/news/tern-701-earns-fda-breakthrough-therapy-designation-in-ph-cml-cancernetwork-fr/ 2026-07-21T02:27:08+00:00 https://keshavmed.com/news/tern-701-earns-fda-breakthrough-therapy-designation-in-ph-cml-cancernetwork-de/ 2026-07-21T02:27:08+00:00 https://keshavmed.com/news/tern-701-earns-fda-breakthrough-therapy-designation-in-ph-cml-cancernetwork-zh-tw/ 2026-07-21T02:27:07+00:00 https://keshavmed.com/news/tern-701-earns-fda-breakthrough-therapy-designation-in-ph-cml-cancernetwork/ 2026-07-21T02:27:06+00:00 https://keshavmed.com/news/fda-approves-oral-nilotinib-tablets-for-ph-cml-oncology-nursing-news-ms/ 2026-07-21T02:26:57+00:00 https://keshavmed.com/news/fda-approves-oral-nilotinib-tablets-for-ph-cml-oncology-nursing-news-vi/ 2026-07-21T02:26:56+00:00 https://keshavmed.com/news/fda-approves-oral-nilotinib-tablets-for-ph-cml-oncology-nursing-news-id/ 2026-07-21T02:26:55+00:00 https://keshavmed.com/news/fda-approves-oral-nilotinib-tablets-for-ph-cml-oncology-nursing-news-th/ 2026-07-21T02:26:55+00:00 https://keshavmed.com/news/fda-approves-oral-nilotinib-tablets-for-ph-cml-oncology-nursing-news-ru/ 2026-07-21T02:26:54+00:00 https://keshavmed.com/news/fda-approves-oral-nilotinib-tablets-for-ph-cml-oncology-nursing-news-es/ 2026-07-21T02:26:53+00:00 https://keshavmed.com/news/fda-approves-oral-nilotinib-tablets-for-ph-cml-oncology-nursing-news-ar/ 2026-07-21T02:26:53+00:00 https://keshavmed.com/news/fda-approves-oral-nilotinib-tablets-for-ph-cml-oncology-nursing-news-pt/ 2026-07-21T02:26:52+00:00 https://keshavmed.com/news/fda-approves-oral-nilotinib-tablets-for-ph-cml-oncology-nursing-news-de/ 2026-07-21T02:26:51+00:00 https://keshavmed.com/news/fda-approves-oral-nilotinib-tablets-for-ph-cml-oncology-nursing-news-ja/ 2026-07-21T02:26:51+00:00 https://keshavmed.com/news/fda-approves-oral-nilotinib-tablets-for-ph-cml-oncology-nursing-news-fr/ 2026-07-21T02:26:50+00:00 https://keshavmed.com/news/fda-approves-oral-nilotinib-tablets-for-ph-cml-oncology-nursing-news-zh-tw/ 2026-07-21T02:26:49+00:00 https://keshavmed.com/news/fda-approves-oral-nilotinib-tablets-for-ph-cml-oncology-nursing-news/ 2026-07-21T02:26:47+00:00 https://keshavmed.com/news/dor-isl-idvynso-hiv-drug-fda-approval-infectious-disease-special-edition-ms/ 2026-07-21T01:30:06+00:00 https://keshavmed.com/news/dor-isl-idvynso-hiv-drug-fda-approval-infectious-disease-special-edition-th/ 2026-07-21T01:30:05+00:00 https://keshavmed.com/news/dor-isl-idvynso-hiv-drug-fda-approval-infectious-disease-special-edition-vi/ 2026-07-21T01:30:05+00:00 https://keshavmed.com/news/dor-isl-idvynso-hiv-drug-fda-approval-infectious-disease-special-edition-id/ 2026-07-21T01:30:04+00:00 https://keshavmed.com/news/dor-isl-idvynso-hiv-drug-fda-approval-infectious-disease-special-edition-ru/ 2026-07-21T01:30:03+00:00 https://keshavmed.com/news/dor-isl-idvynso-hiv-drug-fda-approval-infectious-disease-special-edition-ar/ 2026-07-21T01:30:03+00:00 https://keshavmed.com/news/dor-isl-idvynso-hiv-drug-fda-approval-infectious-disease-special-edition-es/ 2026-07-21T01:30:02+00:00 https://keshavmed.com/news/dor-isl-idvynso-hiv-drug-fda-approval-infectious-disease-special-edition-ja/ 2026-07-21T01:30:01+00:00 https://keshavmed.com/news/dor-isl-idvynso-hiv-drug-fda-approval-infectious-disease-special-edition-pt/ 2026-07-21T01:30:01+00:00 https://keshavmed.com/news/dor-isl-idvynso-hiv-drug-fda-approval-infectious-disease-special-edition-fr/ 2026-07-21T01:30:00+00:00 https://keshavmed.com/news/dor-isl-idvynso-hiv-drug-fda-approval-infectious-disease-special-edition-de/ 2026-07-21T01:30:00+00:00 https://keshavmed.com/news/dor-isl-idvynso-hiv-drug-fda-approval-infectious-disease-special-edition-zh-tw/ 2026-07-21T01:29:59+00:00 https://keshavmed.com/news/dor-isl-idvynso-hiv-drug-fda-approval-infectious-disease-special-edition/ 2026-07-21T01:29:58+00:00 https://keshavmed.com/news/newly-approved-treatment-offers-another-option-for-people-living-with-hiv-says-prism-health-leader-kera-news-ms/ 2026-07-21T01:29:38+00:00 https://keshavmed.com/news/newly-approved-treatment-offers-another-option-for-people-living-with-hiv-says-prism-health-leader-kera-news-th/ 2026-07-21T01:29:37+00:00 https://keshavmed.com/news/newly-approved-treatment-offers-another-option-for-people-living-with-hiv-says-prism-health-leader-kera-news-vi/ 2026-07-21T01:29:37+00:00 https://keshavmed.com/news/newly-approved-treatment-offers-another-option-for-people-living-with-hiv-says-prism-health-leader-kera-news-id/ 2026-07-21T01:29:36+00:00 https://keshavmed.com/news/newly-approved-treatment-offers-another-option-for-people-living-with-hiv-says-prism-health-leader-kera-news-ar/ 2026-07-21T01:29:35+00:00 https://keshavmed.com/news/newly-approved-treatment-offers-another-option-for-people-living-with-hiv-says-prism-health-leader-kera-news-ru/ 2026-07-21T01:29:35+00:00 https://keshavmed.com/news/newly-approved-treatment-offers-another-option-for-people-living-with-hiv-says-prism-health-leader-kera-news-es/ 2026-07-21T01:29:34+00:00 https://keshavmed.com/news/newly-approved-treatment-offers-another-option-for-people-living-with-hiv-says-prism-health-leader-kera-news-pt/ 2026-07-21T01:29:33+00:00 https://keshavmed.com/news/newly-approved-treatment-offers-another-option-for-people-living-with-hiv-says-prism-health-leader-kera-news-ja/ 2026-07-21T01:29:33+00:00 https://keshavmed.com/news/newly-approved-treatment-offers-another-option-for-people-living-with-hiv-says-prism-health-leader-kera-news-de/ 2026-07-21T01:29:32+00:00 https://keshavmed.com/news/newly-approved-treatment-offers-another-option-for-people-living-with-hiv-says-prism-health-leader-kera-news-zh-tw/ 2026-07-21T01:29:31+00:00 https://keshavmed.com/news/newly-approved-treatment-offers-another-option-for-people-living-with-hiv-says-prism-health-leader-kera-news-fr/ 2026-07-21T01:29:31+00:00 https://keshavmed.com/news/newly-approved-treatment-offers-another-option-for-people-living-with-hiv-says-prism-health-leader-kera-news/ 2026-07-21T01:29:30+00:00 https://keshavmed.com/news/til-cell-therapy-in-hiv-positive-patient-with-metastatic-melanoma-case-report-frontiers-ms/ 2026-07-21T01:29:22+00:00 https://keshavmed.com/news/til-cell-therapy-in-hiv-positive-patient-with-metastatic-melanoma-case-report-frontiers-th/ 2026-07-21T01:29:21+00:00 https://keshavmed.com/news/til-cell-therapy-in-hiv-positive-patient-with-metastatic-melanoma-case-report-frontiers-vi/ 2026-07-21T01:29:21+00:00 https://keshavmed.com/news/til-cell-therapy-in-hiv-positive-patient-with-metastatic-melanoma-case-report-frontiers-id/ 2026-07-21T01:29:20+00:00 https://keshavmed.com/news/til-cell-therapy-in-hiv-positive-patient-with-metastatic-melanoma-case-report-frontiers-ar/ 2026-07-21T01:29:19+00:00 https://keshavmed.com/news/til-cell-therapy-in-hiv-positive-patient-with-metastatic-melanoma-case-report-frontiers-ru/ 2026-07-21T01:29:19+00:00 https://keshavmed.com/news/til-cell-therapy-in-hiv-positive-patient-with-metastatic-melanoma-case-report-frontiers-pt/ 2026-07-21T01:29:18+00:00 https://keshavmed.com/news/til-cell-therapy-in-hiv-positive-patient-with-metastatic-melanoma-case-report-frontiers-es/ 2026-07-21T01:29:18+00:00 https://keshavmed.com/news/til-cell-therapy-in-hiv-positive-patient-with-metastatic-melanoma-case-report-frontiers-ja/ 2026-07-21T01:29:17+00:00 https://keshavmed.com/news/til-cell-therapy-in-hiv-positive-patient-with-metastatic-melanoma-case-report-frontiers-fr/ 2026-07-21T01:29:16+00:00 https://keshavmed.com/news/til-cell-therapy-in-hiv-positive-patient-with-metastatic-melanoma-case-report-frontiers-de/ 2026-07-21T01:29:16+00:00 https://keshavmed.com/news/til-cell-therapy-in-hiv-positive-patient-with-metastatic-melanoma-case-report-frontiers-zh-tw/ 2026-07-21T01:29:15+00:00 https://keshavmed.com/news/til-cell-therapy-in-hiv-positive-patient-with-metastatic-melanoma-case-report-frontiers/ 2026-07-21T01:29:14+00:00 https://keshavmed.com/news/two-drug-single-tablet-idvynso-receives-fda-approval-for-hiv-1-infectious-disease-advisor-vi/ 2026-07-21T01:29:06+00:00 https://keshavmed.com/news/two-drug-single-tablet-idvynso-receives-fda-approval-for-hiv-1-infectious-disease-advisor-ms/ 2026-07-21T01:29:06+00:00 https://keshavmed.com/news/two-drug-single-tablet-idvynso-receives-fda-approval-for-hiv-1-infectious-disease-advisor-id/ 2026-07-21T01:29:05+00:00 https://keshavmed.com/news/two-drug-single-tablet-idvynso-receives-fda-approval-for-hiv-1-infectious-disease-advisor-th/ 2026-07-21T01:29:05+00:00 https://keshavmed.com/news/two-drug-single-tablet-idvynso-receives-fda-approval-for-hiv-1-infectious-disease-advisor-ar/ 2026-07-21T01:29:04+00:00 https://keshavmed.com/news/two-drug-single-tablet-idvynso-receives-fda-approval-for-hiv-1-infectious-disease-advisor-ru/ 2026-07-21T01:29:04+00:00 https://keshavmed.com/news/two-drug-single-tablet-idvynso-receives-fda-approval-for-hiv-1-infectious-disease-advisor-es/ 2026-07-21T01:29:03+00:00 https://keshavmed.com/news/two-drug-single-tablet-idvynso-receives-fda-approval-for-hiv-1-infectious-disease-advisor-ja/ 2026-07-21T01:29:02+00:00 https://keshavmed.com/news/two-drug-single-tablet-idvynso-receives-fda-approval-for-hiv-1-infectious-disease-advisor-pt/ 2026-07-21T01:29:02+00:00 https://keshavmed.com/news/two-drug-single-tablet-idvynso-receives-fda-approval-for-hiv-1-infectious-disease-advisor-de/ 2026-07-21T01:29:01+00:00 https://keshavmed.com/news/two-drug-single-tablet-idvynso-receives-fda-approval-for-hiv-1-infectious-disease-advisor-zh-tw/ 2026-07-21T01:29:00+00:00 https://keshavmed.com/news/two-drug-single-tablet-idvynso-receives-fda-approval-for-hiv-1-infectious-disease-advisor-fr/ 2026-07-21T01:29:00+00:00 https://keshavmed.com/news/two-drug-single-tablet-idvynso-receives-fda-approval-for-hiv-1-infectious-disease-advisor/ 2026-07-21T01:28:59+00:00 https://keshavmed.com/news/a-novel-gene-therapy-approach-to-functionally-cure-hiv-succeeds-in-some-monkeys-science-aaas-ms/ 2026-07-21T01:28:51+00:00 https://keshavmed.com/news/a-novel-gene-therapy-approach-to-functionally-cure-hiv-succeeds-in-some-monkeys-science-aaas-vi/ 2026-07-21T01:28:51+00:00 https://keshavmed.com/news/a-novel-gene-therapy-approach-to-functionally-cure-hiv-succeeds-in-some-monkeys-science-aaas-th/ 2026-07-21T01:28:50+00:00 https://keshavmed.com/news/a-novel-gene-therapy-approach-to-functionally-cure-hiv-succeeds-in-some-monkeys-science-aaas-ar/ 2026-07-21T01:28:49+00:00 https://keshavmed.com/news/a-novel-gene-therapy-approach-to-functionally-cure-hiv-succeeds-in-some-monkeys-science-aaas-ru/ 2026-07-21T01:28:49+00:00 https://keshavmed.com/news/a-novel-gene-therapy-approach-to-functionally-cure-hiv-succeeds-in-some-monkeys-science-aaas-id/ 2026-07-21T01:28:49+00:00 https://keshavmed.com/news/a-novel-gene-therapy-approach-to-functionally-cure-hiv-succeeds-in-some-monkeys-science-aaas-pt/ 2026-07-21T01:28:48+00:00 https://keshavmed.com/news/a-novel-gene-therapy-approach-to-functionally-cure-hiv-succeeds-in-some-monkeys-science-aaas-es/ 2026-07-21T01:28:48+00:00 https://keshavmed.com/news/a-novel-gene-therapy-approach-to-functionally-cure-hiv-succeeds-in-some-monkeys-science-aaas-de/ 2026-07-21T01:28:47+00:00 https://keshavmed.com/news/a-novel-gene-therapy-approach-to-functionally-cure-hiv-succeeds-in-some-monkeys-science-aaas-ja/ 2026-07-21T01:28:47+00:00 https://keshavmed.com/news/a-novel-gene-therapy-approach-to-functionally-cure-hiv-succeeds-in-some-monkeys-science-aaas-zh-tw/ 2026-07-21T01:28:46+00:00 https://keshavmed.com/news/a-novel-gene-therapy-approach-to-functionally-cure-hiv-succeeds-in-some-monkeys-science-aaas-fr/ 2026-07-21T01:28:46+00:00 https://keshavmed.com/news/a-novel-gene-therapy-approach-to-functionally-cure-hiv-succeeds-in-some-monkeys-science-aaas/ 2026-07-21T01:28:45+00:00 https://keshavmed.com/news/expanded-tb-screening-in-hiv-wards-fails-to-speed-treatment-clinical-trial-shows-medical-xpress-ms/ 2026-07-21T01:28:38+00:00 https://keshavmed.com/news/expanded-tb-screening-in-hiv-wards-fails-to-speed-treatment-clinical-trial-shows-medical-xpress-vi/ 2026-07-21T01:28:37+00:00 https://keshavmed.com/news/expanded-tb-screening-in-hiv-wards-fails-to-speed-treatment-clinical-trial-shows-medical-xpress-id/ 2026-07-21T01:28:36+00:00 https://keshavmed.com/news/expanded-tb-screening-in-hiv-wards-fails-to-speed-treatment-clinical-trial-shows-medical-xpress-th/ 2026-07-21T01:28:36+00:00 https://keshavmed.com/news/expanded-tb-screening-in-hiv-wards-fails-to-speed-treatment-clinical-trial-shows-medical-xpress-ru/ 2026-07-21T01:28:36+00:00 https://keshavmed.com/news/expanded-tb-screening-in-hiv-wards-fails-to-speed-treatment-clinical-trial-shows-medical-xpress-es/ 2026-07-21T01:28:35+00:00 https://keshavmed.com/news/expanded-tb-screening-in-hiv-wards-fails-to-speed-treatment-clinical-trial-shows-medical-xpress-ar/ 2026-07-21T01:28:35+00:00 https://keshavmed.com/news/expanded-tb-screening-in-hiv-wards-fails-to-speed-treatment-clinical-trial-shows-medical-xpress-ja/ 2026-07-21T01:28:34+00:00 https://keshavmed.com/news/expanded-tb-screening-in-hiv-wards-fails-to-speed-treatment-clinical-trial-shows-medical-xpress-pt/ 2026-07-21T01:28:34+00:00